Biden’s Infrastructure Bill Sees the Light of Day

This year’s budget proposal season is a little spicy as it’s the first major budget haggling of Biden’s administration, and it seems to be focusing heavily on goals he campaigned on; funding for more equitable education, pollution reduction, and a 110 billion dollar transportation package.

That infrastructure package is now more of a reality, and the implications for various industries will be hard to quantify.

The Biden Administration plans to invest heavily in post-pandemic economic recovery, with the education, transportation, and public works industries looking to receive massive funding boosts. The proposals still need to work their way through Congress, but if the recent infrastructure package negotiations are a foresight into the future, there is sure to be much debate over the new budget.
 
The sweeping bipartisan 100 trillion dollar package that passed the Senate on August 10th is the largest federal investment in the nation’s aging public works system in more than a decade, with the Senate voting 69-30. Like Alix Steel and David Westin explained on Bloomberg, this is both unexpected and also raises an eyebrow to a potentially larger trend of bipartisan cooperation.

“But yet, a bipartisan spending with over $500 billion of new money is now small feat for a very partisan DC.”
-Alix Steel, Host, Bloomberg

“That’s absolutely right, though there were actually three fiscal stimulus bills that got through on a bipartisan basis under President Trump I should say. The partisan one came up with the American Rescue Plan which was actually President Biden at the beginning of this year.”
-David Westin, Host, Bloomberg

The bill would see about $110 billion would go to roads, bridges and other transportation projects. It gives Amtrak the most funding it has received since it was founded in 1971. It also included $65 billion meant to connect hard-to-reach rural communities to high-speed internet and help sign up low-income city dwellers who cannot afford it

For continued updates on the upcoming budget debates and their impact across the B2B world, subscribe to the Homepage of B2B today. 

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More